Phibro Animal Health Corporation
PHIBRO ANIMAL HEALTH CORP (Form: 8-K, Received: 07/24/2017 16:22:25)

  

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

  

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): July 24, 2017 (July 24, 2017)

 

Phibro Animal Health Corporation

 

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

 

 

Delaware

 

01-36410

 

13-1840497

(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)

 

 

Glenpointe Centre East, 3rd Floor

300 Frank W. Burr Boulevard, Suite 21

Teaneck, New Jersey 07666-6712

 

(Address of Principal Executive Offices, including Zip Code)

 

 

(201) 329-7300

 

(Registrant’s telephone number, including area code)

 

Not Applicable

 

(Former name or former address, if changed since last report)

   

 

Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

     

 

   

ITEM 8.01 OTHER EVENTS

 

On July 24, 2017, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on September 27, 2017, to stockholders of record at the close of business on September 6, 2017. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits

 

Exhibit

Number

 

 

Description

     
99.1   Press Release, dated July 24, 2017. 

 

     

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

PHIBRO ANIMAL HEALTH CORPORATION

Registrant

   
Date: July 24, 2017  
   
  By:  /s/ Thomas G. Dagger
  Name:  Thomas G. Dagger
  Title: Senior Vice President, General Counsel and Corporate Secretary

  

     

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 99.1

  

PHIBRO_LOGO_B

 

 

 

Phibro Animal Health Corporation Declares Quarterly Dividend

 

TEANECK, N.J., July 24, 2017 (GLOBE NEWSWIRE) – The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on September 27, 2017, to stockholders of record at the close of business on September 6, 2017.

 

About Phibro Animal Health Corporation

 

Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. For further information, please visit www.pahc.com.

 

Contact:

Richard Johnson

Chief Financial Officer, Phibro Animal Health Corporation

+1 201-329-7300

investor.relations@pahc.com